162 related articles for article (PubMed ID: 35732097)
1. New therapeutic strategies based on biasing IL-2 mutants for cancers and autoimmune diseases.
Jin D; Jiang Y; Chang L; Wei J; Sun J
Int Immunopharmacol; 2022 Sep; 110():108935. PubMed ID: 35732097
[TBL] [Abstract][Full Text] [Related]
2. New therapeutic strategies based on IL-2 to modulate Treg cells for autoimmune diseases.
Xu L; Song X; Su L; Zheng Y; Li R; Sun J
Int Immunopharmacol; 2019 Jul; 72():322-329. PubMed ID: 31005777
[TBL] [Abstract][Full Text] [Related]
3. Molecular Engineering of Interleukin-2 for Enhanced Therapeutic Activity in Autoimmune Diseases.
Tomasovic LM; Liu K; VanDyke D; Fabilane CS; Spangler JB
BioDrugs; 2024 Mar; 38(2):227-248. PubMed ID: 37999893
[TBL] [Abstract][Full Text] [Related]
4. A systematic review of interleukin-2-based immunotherapies in clinical trials for cancer and autoimmune diseases.
Raeber ME; Sahin D; Karakus U; Boyman O
EBioMedicine; 2023 Apr; 90():104539. PubMed ID: 37004361
[TBL] [Abstract][Full Text] [Related]
5. Natural and modified IL-2 for the treatment of cancer and autoimmune diseases.
Mizui M
Clin Immunol; 2019 Sep; 206():63-70. PubMed ID: 30415086
[TBL] [Abstract][Full Text] [Related]
6. A single-agent fusion of human IL-2 and anti-IL-2 antibody that selectively expands regulatory T cells.
Lin Y; Wang X; Qin Y; Wang C; Zhou T; Zhang L; Su L; Ren W; Liao C
Commun Biol; 2024 Mar; 7(1):299. PubMed ID: 38461332
[TBL] [Abstract][Full Text] [Related]
7. A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease.
Peterson LB; Bell CJM; Howlett SK; Pekalski ML; Brady K; Hinton H; Sauter D; Todd JA; Umana P; Ast O; Waldhauer I; Freimoser-Grundschober A; Moessner E; Klein C; Hosse RJ; Wicker LS
J Autoimmun; 2018 Dec; 95():1-14. PubMed ID: 30446251
[TBL] [Abstract][Full Text] [Related]
8. Engineered human cytokine/antibody fusion proteins expand regulatory T cells and confer autoimmune disease protection.
VanDyke D; Iglesias M; Tomala J; Young A; Smith J; Perry JA; Gebara E; Cross AR; Cheung LS; Dykema AG; Orcutt-Jahns BT; Henclová T; Golias J; Balolong J; Tomasovic LM; Funda D; Meyer AS; Pardoll DM; Hester J; Issa F; Hunter CA; Anderson MS; Bluestone JA; Raimondi G; Spangler JB
Cell Rep; 2022 Oct; 41(3):111478. PubMed ID: 36261022
[TBL] [Abstract][Full Text] [Related]
9. Fine tuning subsets of CD4
Zhao Z; Zhang X; Su L; Xu L; Zheng Y; Sun J
Int Immunopharmacol; 2018 Mar; 56():269-276. PubMed ID: 29414661
[TBL] [Abstract][Full Text] [Related]
10. MK-6, a novel not-α IL-2, elicits a potent antitumor activity by improving the effector to regulatory T cell balance.
Kobayashi M; Kojima K; Murayama K; Amano Y; Koyama T; Ogama N; Takeshita T; Fukuhara T; Tanaka N
Cancer Sci; 2021 Nov; 112(11):4478-4489. PubMed ID: 34545658
[TBL] [Abstract][Full Text] [Related]
11. Application of IL-2 therapy to target T regulatory cell function.
Shevach EM
Trends Immunol; 2012 Dec; 33(12):626-32. PubMed ID: 22951308
[TBL] [Abstract][Full Text] [Related]
12. ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy.
Lopes JE; Fisher JL; Flick HL; Wang C; Sun L; Ernstoff MS; Alvarez JC; Losey HC
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32317293
[TBL] [Abstract][Full Text] [Related]
13. IL-2-based approaches to Treg enhancement.
Harris F; Berdugo YA; Tree T
Clin Exp Immunol; 2023 Mar; 211(2):149-163. PubMed ID: 36399073
[TBL] [Abstract][Full Text] [Related]
14. Human regulatory T cell suppressive function is independent of apoptosis induction in activated effector T cells.
Vercoulen Y; Wehrens EJ; van Teijlingen NH; de Jager W; Beekman JM; Prakken BJ
PLoS One; 2009 Sep; 4(9):e7183. PubMed ID: 19779623
[TBL] [Abstract][Full Text] [Related]
15. Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma.
Attia P; Maker AV; Haworth LR; Rogers-Freezer L; Rosenberg SA
J Immunother; 2005; 28(6):582-92. PubMed ID: 16224276
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic potential of interleukin-2 in autoimmune diseases.
Yuan Y; Kolios AGA; Liu Y; Zhang B; Li H; Tsokos GC; Zhang X
Trends Mol Med; 2022 Jul; 28(7):596-612. PubMed ID: 35624009
[TBL] [Abstract][Full Text] [Related]
17. Revisiting IL-2: Biology and therapeutic prospects.
Abbas AK; Trotta E; R Simeonov D; Marson A; Bluestone JA
Sci Immunol; 2018 Jul; 3(25):. PubMed ID: 29980618
[TBL] [Abstract][Full Text] [Related]
18. Interleukin 2 in the pathogenesis and therapy of type 1 diabetes.
Rosenzwajg M; Churlaud G; Hartemann A; Klatzmann D
Curr Diab Rep; 2014 Dec; 14(12):553. PubMed ID: 25344788
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-2 therapy of cancer-clinical perspectives.
Majidpoor J; Mortezaee K
Int Immunopharmacol; 2021 Sep; 98():107836. PubMed ID: 34218217
[TBL] [Abstract][Full Text] [Related]
20. Potential use of IL-2/anti-IL-2 antibody immune complexes for the treatment of cancer and autoimmune disease.
Boyman O; Surh CD; Sprent J
Expert Opin Biol Ther; 2006 Dec; 6(12):1323-31. PubMed ID: 17223740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
